News

Becker's Hospital Review1y
Home administration of pegfilgrastim reduces disease by 32%, Cigna finds
A Cigna Healthcare study found administering pegfilgrastim, an injection used to prevent infection in cancer patients, in a home setting increased patient outcomes compared to administration in a ...
Monthly Prescribing Reference2y
Autoinjector Presentation of Pegfilgrastim Biosimilar Udenyca Now Available
Credit: Coherus BioSciences. Training should be provided to patients and caregivers on how to appropriately administer Udenyca via the prefilled autoinjector. Udenyca ® (pegfilgrastim-cbqv), a ...
Nasdaq1y
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
“Our market studies showed a significant demand for a novel on-body pegfilgrastim delivery device tailored to specific patient needs. We expect that UDENYCA ONBODY’s five-minute injection time ...
Nature4y
Developing a pegfilgrastim biosimilar to increase patient access to cancer care
The group structure gives Cinfa Biotech the support ... a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are formulations ...
Business Wire3y
Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA ® (pegfilgrastim-pbbk)
According to IQVIA ®, U.S. annual sales for pegfilgrastim for the 12 months ended March 2022 were $3.1 billion, $1.0 billion of which represented biosimilar sales. Indications: FYLNETRA is a ...